David M. Miller

6.0k total citations · 3 hit papers
119 papers, 4.1k citations indexed

About

David M. Miller is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, David M. Miller has authored 119 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 34 papers in Molecular Biology and 16 papers in Epidemiology. Recurrent topics in David M. Miller's work include Polyomavirus and related diseases (16 papers), Nonmelanoma Skin Cancer Studies (12 papers) and Cutaneous Melanoma Detection and Management (10 papers). David M. Miller is often cited by papers focused on Polyomavirus and related diseases (16 papers), Nonmelanoma Skin Cancer Studies (12 papers) and Cutaneous Melanoma Detection and Management (10 papers). David M. Miller collaborates with scholars based in United States, United Kingdom and Australia. David M. Miller's co-authors include A.E. Bender, Howard L. Kaufman, Sheldon Baumrind, Sophia Z. Shalhout, Kevin S. Emerick, Robert Molthen, Rizwan Haq, Nicholas Macedo, Grant D. Geske and Jennifer C. O’Neill and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

David M. Miller

108 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Determination of the Net Utilization of Proteins by a Shortened Method

1955 362 citations David M. Miller et al. profile →
Therapy with oncolytic viruses: progress and challenges

2023 342 citations Sophia Z. Shalhout, David M. Miller et al. Nature Reviews Clinical Oncology profile →
Clinical landscape of oncolytic virus research in 2020

2020 242 citations David M. Miller, Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Countries citing papers authored by David M. Miller

Since Specialization

Citations

This map shows the geographic impact of David M. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Miller more than expected).

Fields of papers citing papers by David M. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Miller. The network helps show where David M. Miller may publish in the future.

Co-authorship network of co-authors of David M. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Miller. A scholar is included among the top collaborators of David M. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Miller. David M. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunotherapy for Advanced Conjunctival Squamous Cell Carcinoma: Treatment Failures 2025 ·Ophthalmic Plastic and Reconstructive Surgery ·Amee D. Azad, (unknown), Kevin S. Emerick, Sophia Z. Shalhout, Howard L. Kaufman, David M. Miller, Grace Lee, Michael K. Yoon, Suzanne K. Freitag, Anna M. Stagner, Natalie Wolkow	1
2	Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain 2025 ·David M. Miller, Vernon K. Sondak, Sunandana Chandra, Vatche Tchekmedyian, Ryan J. Sullivan, Ross D. Merkin, Vishal Patel, Adewole S. Adamson, Isaac Brownell, Reed E. Drews, Nikhil I. Khushalani, Shailender Bhatia, Paul Nghiem	0
3	Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma 2024 ·JAMA Otolaryngology–Head & Neck Surgery ·Emily Kim, Emily S. Ruiz, (unknown), Sophia Z. Shalhout, Glenn J. Hanna, David M. Miller, Chrysalyne D. Schmults, Eleni M. Rettig, Ruth K. Foreman, Rosh K.V. Sethi, Manisha Thakuria, Ann W. Silk	10
4	Should Ipilimumab Be the New “Standard” for Refractory MCC? 2024 ·David M. Miller	1
5	Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard? 2023 ·(unknown), David M. Miller, Howard L. Kaufman, Kevin S. Emerick, (unknown), Sophia Z. Shalhout, (unknown), Emily Kim, Vishal Patel, (unknown), Sameer Gupta, Isaac Brownell	1
6	Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time? 2023 ·Emily Kim, Sophia Z. Shalhout, Howard L. Kaufman, Kevin S. Emerick, (unknown), Vishal Patel, (unknown), Isaac Brownell, David M. Miller	2
7	Therapy with oncolytic viruses: progress and challenges breakdown → 2023 ·Nature Reviews Clinical Oncology ·Sophia Z. Shalhout, David M. Miller, Kevin S. Emerick, Howard L. Kaufman	342
8	Neoadjuvant Nivo/Rela for Resectable Melanoma 2022 ·David M. Miller, Howard L. Kaufman, Kevin S. Emerick, (unknown), Justine V. Cohen, Emily Kim, Sophia Z. Shalhout	2
9	Neoadjuvant ICI for Resectable CSCC 2022 ·David M. Miller, Vishal Patel, Justine V. Cohen, (unknown), Sophia Z. Shalhout, (unknown)	0
10	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma 2018 ·Journal of Investigative Dermatology ·Philip Eliades, Brian J. Abraham, Zhenyu Ji, David M. Miller, Camilla L. Christensen, Nicholas Kwiatkowski, Raj Kumar, Ching Ni Njauw, Michael Taylor, Benchun Miao, Tinghu Zhang, Kwok‐Kin Wong, Nathanael S. Gray, Richard A. Young, Hensin Tsao	42
11	Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab 2018 ·Journal for ImmunoTherapy of Cancer ·David M. Miller, (unknown), Anupam M. Desai, Reed E. Drews	6
12	Clinical spectrum of cutaneous melanoma morphology 2018 ·Journal of the American Academy of Dermatology ·Nikolai Klebanov, Nicole Gunasekera, William M. Lin, Elena B. Hawryluk, David M. Miller, Bobby Y. Reddy, Mitalee P. Christman, (unknown), (unknown), Lyn M. Duncan, Arthur J. Sober, Hensin Tsao	13
13	Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade 2017 ·JAAD Case Reports ·David M. Miller, Beverly E. Faulkner-Jones, James R. Stone, Reed E. Drews	39
14	Network Efficiency As A Final Common Pathway For Cognitive Deficits In Multiple Sclerosis: A Single Network Graph Theory Study (P6.128) 2014 ·Neurology ·Matteo Pardini, Varun Sethi, Nils Muhlert, Özgür Yaldizli, Fulvia Palesi, Daniel R. Altmann, María A. Ron, Claudia A. M. Gandini Wheeler‐Kingshott, David M. Miller, Declan Chard	2
15	TLR Agonists Prevent the Establishment of Allogeneic Hematopoietic Chimerism in Mice Treated with Costimulation Blockade, 2009 ·The Journal of Immunology ·David M. Miller, Thomas B. Thornley, Todd Pearson, Annie J. Kruger, Masahiro Yamazaki, Leonard D. Shultz, Raymond M. Welsh, Michael A. Brehm, Aldo A. Rossini, Dale L. Greiner	11
16	Different Mechanisms Control Peripheral and Central Tolerance in Hematopoietic Chimeric Mice 2007 ·American Journal of Transplantation ·Masahiro Yamazaki, Todd Pearson, Michael A. Brehm, David M. Miller, (unknown), Thomas G. Markees, Leonard D. Shultz, John P. Mordes, Aldo A. Rossini, D.L. Greiner	21
17	Multi-factor analysis of firm-level performance through feed-forward, feed-back relationships 1998 ·Winter Simulation Conference ·Young H. Park, David M. Miller	1
18	Immunological evidence for a conformational difference between recombinant bovine rhodanese and rhodanese purified from bovine liver 1992 ·Journal of Protein Chemistry ·Gerald A. Merrill, David M. Miller, John M. Chirgwin, (unknown)	6
19	Optics and Contrast Questions Connected with the Multifocal IOL 1991 ·David M. Miller	1
20	Healon (sodium hyaluronate) : a guide to its use in opthalmic surgery 1983 ·J. Wiley eBooks ·David M. Miller, Robert Stegmann	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact